i think the mono trial is unaffected except to the extent that i remember some saying, maybe yesterday in hte call, that Cytodyn planned to obtain approval for leronlimab with a Supplementary NDA once the combo therapy was approved.

So to the extent the combo approval is delayed, perhaps the mono approval may be delayed as well.

but i know really nothing about how an SNDA works so my comments are very likely all wrong.